Expression of the Glycodelin A Gene and the Detection of its Protein in Tissues and Serum of Ovarian Carcinoma Patients

Background: Glycodelin A (GdA), also known as placental protein 14 (PP14), has been detected in endometrial, cervical and ovarian carcinoma cells. It is suspected to be a marker of human ovarian cancer tissues. Materials and Methods: We investigated serum, tissue and cyst fluid samples of patients w...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 27; no. 4A; pp. 2023 - 2025
Main Authors RICHTER, C, BAETJE, M, BISCHOF, A, MAKOVITZKY, J, RICHTER, D. U, GERBER, B, BRIESE, V
Format Journal Article Conference Proceeding
LanguageEnglish
Published Attiki International Institute of Anticancer Research 01.07.2007
Subjects
Biological and medical sciences
Biomarkers, Tumor - analysis
Enzyme-Linked Immunosorbent Assay
Female
Female genital diseases
Gene Expression
Glycodelin
Glycoproteins - biosynthesis
Glycoproteins - genetics
Gynecology. Andrology. Obstetrics
Humans
Immunohistochemistry
Medical sciences
Ovarian Neoplasms - diagnosis
Ovarian Neoplasms - metabolism
Polymerase Chain Reaction
Pregnancy Proteins - biosynthesis
Pregnancy Proteins - genetics
RNA, Messenger - analysis
Sensitivity and Specificity
Tumors
Human
Ovary carcinoma
Ovary cancer
Placental protein PP14
ovarian carcinoma
Malignant tumor
Gene expression
Serum protein
Female genital diseases
Ovarian diseases
Cancerology
Glycodelin A (GdA)
Diagnosis
placental protein 14 (PP14)
Online AccessGet full text

Cover

More Information
Summary:Background: Glycodelin A (GdA), also known as placental protein 14 (PP14), has been detected in endometrial, cervical and ovarian carcinoma cells. It is suspected to be a marker of human ovarian cancer tissues. Materials and Methods: We investigated serum, tissue and cyst fluid samples of patients with an ovarian carcinoma in contrast to patients with benign and malignant diseases such as uterine myoma, endometriosis, cervical, uterine and breast cancer, and metastases of bladder and colon carcinoma. Used methods were enzyme-immunoassay, immuno-histochemistry (IHC) and polymerase chain reaction (PCR). Results: In 81% of the control group the GdA-expression was negative, which was confirmed by IHC and PCR. Of the ovarian carcinoma group only 52% showed correspondence between IHC and PCR. Conclusion: These results indicate that determination of GdA is not sensitive or specific enough for use as a tumour marker.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0250-7005
1791-7530